title: Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
abstract: Sera from 86 patients with chronic hepatitis C virus (HCV) infection treated with recombinant interferons-alpha (rIFN-alpha) were screened for IFN-binding and antiviral effect-neutralizing antibodies. Out of the 61 patients treated with rIFN-alpha2b, 46% had binding and 28% had neutralizing antibodies. 44% of the 25 patients treated with rIFN-alpha2a developed binding antibodies and 24% had neutralizing antibodies. Contradictory data were observed concerning the appearance of anti-IFN antibodies and the outcome of IFN therapy. A significantly higher number of the patients with a sustained response to rIFN-alpha2b therapy formed antibodies than the number among the non-responder patients. At the same time, in the patients treated with rIFN-alpha2a, opposite data were found. The activity of the antibodies in some sera was studied against the antiproliferative effect of IFNs on Daudi cells by measuring the [3H]thymidine incorporation. The binding antibodies without neutralization of the antiviral effect of the IFNs inhibited the antiproliferative activity of the rIFNs, similarly to antibodies having both IFN-binding and antiviral effect-neutralizing capacities. At the same time, the antiproliferative effect of the natural IFN was less affected. It is suggested that the antiproliferative assay is more sensitive than the antiviral method for demonstration of the presence of antibodies exerting an inhibitory effect on the biological activities of IFN.
authors.affiliation: Department of Optics and Quantum Electronics, University of Szeged, Hungary.
authors.forename: Erzsébet
authors.initials: E
authors.lastname: Bálint
authors.forename: Márta
authors.initials: M
authors.lastname: Bakay
authors.forename: Klára
authors.initials: K
authors.lastname: Onody
authors.forename: F
authors.initials: F
authors.lastname: Farkas
authors.forename: G
authors.initials: G
authors.lastname: Horváth
authors.forename: Gy
authors.initials: G
authors.lastname: Tolvaj
authors.forename: K
authors.initials: K
authors.lastname: Dávid
authors.forename: Margit
authors.initials: M
authors.lastname: Horányi
authors.forename: Ilona
authors.initials: I
authors.lastname: Béládi
mesh_terms: D000328:Adult; D000368:Aged; D000918:Antibody Specificity; D000998:Antiviral Agents / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D016898:Interferon-alpha / Q000037:antagonists & inhibitors* / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins